Core Insights - The collaboration between Nocera Biopharma and Zenas BioPharma involves a global licensing agreement worth over $2 billion, focusing on the development of Orelabrutinib for multiple sclerosis and other autoimmune diseases [2][4]. Group 1: Agreement Details - Zenas will receive global exclusive rights for Orelabrutinib in the multiple sclerosis field and rights for non-oncology development and commercialization outside Greater China and Southeast Asia [4][5]. - Nocera Biopharma will receive an upfront payment of $100 million, milestone payments, and 7 million shares of common stock from Zenas, along with royalties of up to a percentage of annual net sales from licensed products [4][6]. Group 2: Product Potential - Orelabrutinib is the first highly permeable BTK inhibitor for the central nervous system to enter Phase III clinical trials, with trials for primary progressive multiple sclerosis (PPMS) starting in Q3 2025 and secondary progressive multiple sclerosis (SPMS) trials expected to begin in Q1 2026 [4][8]. - The drug has shown significant efficacy in reducing brain inflammation and has an excellent safety profile based on Phase II data [4][8]. Group 3: Strategic Focus - Nocera Biopharma retains global rights for Orelabrutinib in oncology and non-oncology rights in Greater China and Southeast Asia, indicating a strategic focus on dual therapeutic areas [6][8]. - The company aims to enhance its drug discovery platform to develop first-in-class and best-in-class therapies for autoimmune diseases, addressing unmet medical needs in China and globally [9].

Market Overview - Hong Kong stocks experienced a familiar pattern during the National Day holiday, with the Hang Seng Index dropping by 0.48% after one day of increase followed by three days of adjustment [1] - The U.S. government faced a shutdown starting October 1, affecting over 100,000 federal employees, with potential long-term negative impacts if the shutdown persists [1] - China's gold reserves increased to 7,406 million ounces by the end of September, marking the 11th consecutive month of accumulation [1] Gold and Silver Market - Ray Dalio, founder of Bridgewater, suggested that gold is a better hedge than the dollar and recommended a 15% allocation in investment portfolios as gold approaches $4,000 per ounce [2] - Chinese gold stocks such as Zijin Mining and Shandong Gold saw significant price increases, with Zijin rising over 13% and Shandong over 7% [2] - Silver prices also rose, with spot silver reaching $48.32 per ounce, reflecting a daily increase of 1% [2] Automotive Industry - The U.S. automotive sector is facing challenges, particularly after a fire at Novelis' Oswego plant, which supplies 40% of aluminum sheets for the industry, leading to production halts expected to last until early next year [2] - Tesla launched a "simplified" version of the Model Y at a lower price, but market reception appears lukewarm due to reduced features [2] Electric Vehicle Market - Chinese electric vehicle manufacturers are showing strong performance in Europe, with a 35% year-on-year increase in sales across nine major countries in September [3] - Companies like Xpeng, Geely, and BYD are expected to maintain positive trends as new models are set to launch in Q4 [3] Battery Technology - Advances in solid-state battery technology are being reported, with new materials developed that significantly enhance energy density [3] - Production rates are expected to increase by 5-10% in October, with a projected year-on-year growth of 30-50% [3] AI and Semiconductor Industry - OpenAI announced a partnership with AMD to deploy 6 GW of AMD GPU computing power, indicating continued investment in AI technology [4] - Nvidia is expected to play a significant role in a $20 billion funding round for Elon Musk's AI startup, xAI, highlighting the ongoing collaboration in the AI sector [4] Nuclear Fusion Developments - The BEST project in Anhui, China, achieved a key breakthrough, marking progress in nuclear fusion technology [5] - Germany plans to invest €2 billion in building the world's first nuclear fusion power plant by 2029 [5] Pharmaceutical Sector - Innovent Biologics announced a licensing agreement with Zenas Bio Pharma for the development and commercialization of its product, with potential total payments exceeding $2 billion [6] - Other companies in the sector may see increased activity due to potential milestone payments related to this agreement [6] Mining and Materials - China Metallurgical Group reported a decrease in new contract amounts but an increase in overseas contracts, indicating a shift in focus towards international operations [7] - The company is advancing projects in Afghanistan and Pakistan, which are expected to yield significant profits upon completion [8] - The company also has a strong position in silicon-based semiconductor materials, indicating long-term investment potential [9]

⑦【斯特兰蒂斯任命Ciancia为全球制造主管】全球第四大汽车制造商斯特兰蒂斯（Stellantis）周三宣布，Francesco Ciancia将于11月1日重新加入公司，担 任全球制造主管和斯特兰蒂斯领导力团队（SLT）的成员。 每经记者｜宋欣悦 每经编辑｜何小桃 兰素英 向江林 ①【三大期指齐涨】截至发稿，道指期货涨0.17%、标普500指数期货涨0.15%、纳指期货涨0.19%。 ②【中概股盘前涨跌不一】中概股盘前涨跌不一，阿里巴巴涨0.45%，拼多多涨0.03%，京东跌0.29%，百度跌0.39%，理想汽车涨0.95%。 ③【美国官网上线低价版Model Y和Model 3，特斯拉盘前涨1.2%】特斯拉盘前涨超1.2%。消息面上，当地时间周二，特斯拉官网更新Model Y和Model 3 标准版的订购信息。Model Y的标准版目前在美国市场起售价为3.999万美元，较此前Model Y的起售价便宜约11%。Model 3标准版起售价3.699万美元，为 特斯拉目前最便宜的车型。 ④【现货黄金站上4040美元续刷新高，黄金股盘前普涨】10月8日，现货黄金站上4040美元/盎司，续创历史新高。黄金股盘 ...

Core Insights - InnoCare Pharma Inc., a wholly-owned subsidiary of the company, has signed a licensing agreement with Zenas BioPharma, granting Zenas global development and commercialization rights for Orelabrutinib in multiple sclerosis and other non-oncology therapeutic areas [1] - Zenas will pay up to $100 million in upfront and milestone payments, with total transaction value exceeding $2 billion, including stock issuance and royalties [1] Group 1 - The agreement includes rights to two preclinical molecules: a novel oral IL-17 AA/AF inhibitor and a brain-penetrant oral TYK2 inhibitor [1] - Zenas will issue 7 million shares of common stock to the company, with additional payments tied to clinical development, registration, and commercialization milestones [1] - The company is entitled to receive tiered royalties of up to the high teens percentage on annual net sales of the licensed products [1]

Core Insights - The article highlights significant fluctuations in the market prices of silver and tin, which have impacted the stock price of Xingye Silver Tin [1] Performance - Chipone Technology expects a record high quarterly revenue of 1.284 billion yuan for Q3 [1] - Great Wall Motors reported a year-on-year sales increase of 23.29% in September [1] - Foton Motor's total vehicle sales in September grew by 6.08% year-on-year, with new energy vehicle sales increasing by 47.77% [1] - BYD experienced a year-on-year decline of 5.52% in new energy vehicle sales in September [1] - Seres saw a year-on-year sales increase of 8.33% in September [1] - BAIC Blue Valley's subsidiary reported a year-on-year sales increase of 30.15% in September [1] - Yonghe Holdings anticipates a year-on-year net profit increase of 211.59% to 225.25% for the first three quarters [1] Shareholding Changes - Huaxing Yuanchuang's shareholders plan to reduce their holdings by no more than 0.9% [1] - Ruile New Materials' shareholders intend to reduce their holdings by no more than 100,800 shares [1] Share Buybacks - Huaxin Cement plans to repurchase shares worth between 32.25 million and 64.5 million yuan [1] Contract Awards - Bomei Technology signed a contract for an offshore floating production storage and offloading vessel project, valued at approximately 190 to 240 million USD [1] - Sichuan Gold acquired exploration rights for the Kugezi-Juebei gold mine in Xinjiang [1] - Weisheng Information won projects totaling 287 million yuan, accounting for 10.45% of the company's expected revenue for 2024 [1] - Innovent Biologics' subsidiary signed a licensing agreement for the drug Orelabrutinib and two preclinical assets, with a total transaction value exceeding 2 billion USD [1] - Runjian Co. plans to bid for a land-based wind power project worth 1.753 billion yuan [1] - Xinjiang Jiaojian intends to bid for a highway construction project valued at 483 million yuan [1] Equity Changes - Delixi Holdings is planning a change in company control, leading to a stock suspension [1] - Bofei Electric plans to transfer 100% equity of its wholly-owned subsidiary Bofei New Energy [1] Other Developments - Dianguang Media holds 4.1288 million shares of Ruili Technology through Dacheng Venture Capital, representing 2.2915% of its post-issue total share capital [1] - Huaxin Cement has terminated plans for a spin-off listing of its overseas subsidiary [1] - Baili Tianheng received approval for clinical trials of BL-ARC001 for late-stage solid tumor treatment [1] - *ST Gaohong received a notice of termination of listing [1] - *ST Jianyi plans to sign an agreement to terminate the investment cooperation for the monocrystalline silicon project and deregister Jianyi Zhengyao [1]

Major Events - Delixi Co., Ltd. is planning a change in control, with stock suspension starting from October 9, 2025, for up to two trading days [1] - Sichuan Gold has won the exploration rights for the Kugez—Juebei gold mine in Xinjiang for 510 million yuan, indicating significant mining potential in a key mineral belt [1] - *ST Gaohong received a notice of termination of listing due to stock prices being below 1 yuan for 20 consecutive trading days [2] - Baili Tianheng's innovative drug BL-ARC001 has received clinical trial approval for treating advanced solid tumors, marking a significant advancement in targeted therapy [3] - Xingye Silver Tin's stock price fluctuation is attributed to significant recent price changes in its main products, silver and tin [3] Performance Overview - BAIC Blue Valley's subsidiary reported a 30.15% year-on-year increase in September sales, totaling 20,539 vehicles [4] - Seres achieved a 19.44% year-on-year increase in September sales, reaching 44,700 new energy vehicles [4] - BYD's September sales of new energy vehicles decreased by 5.52% year-on-year, totaling 396,300 vehicles, with exports of 71,256 vehicles [5] - Chipone Technology expects Q3 revenue of 1.284 billion yuan, a 119.74% increase from the previous quarter and a 78.77% increase year-on-year [5] - Yonghe Holdings anticipates a net profit increase of 448% to 507% for Q3, with projected profits of 456 million to 476 million yuan for the first three quarters [5] Major Contracts - Xinjiang Jiaojian has been awarded a 483 million yuan highway construction project [6] - Longquan Co. is a candidate for a project worth 50.76 million yuan, expected to positively impact revenue and profit [7] - Runjian Co. has secured a design and construction contract for a land-based wind power project valued at 1.753 billion yuan [8] - Innovent Biologics has signed a licensing agreement with Zenas BioPharma for the drug Obrutinib and two preclinical assets, with a total deal value exceeding 2 billion USD [8] Shareholding Changes - Huaxing Yuanchuang announced plans for its employee shareholding platforms to reduce their holdings by up to 0.9% of the company's total shares [9][10]

⑦【斯特兰蒂斯任命Ciancia为全球制造主管】全球第四大汽车制造商斯特兰蒂斯（Stellantis）周三宣 布，Francesco Ciancia将于11月1日重新加入公司，担任全球制造主管和斯特兰蒂斯领导力团队（SLT） 的成员。 ⑧【亚马逊计划2027年前在比利时投资11.6亿美元】10月8日，据媒体报道，美国科技巨头亚马逊计划 在2025年至2027年期间，向比利时投资10亿欧元（约合11.6亿美元）。 ①【三大期指齐涨】截至发稿，道指期货涨0.17%、标普500指数期货涨0.15%、纳指期货涨0.19%。 ②【中概股盘前涨跌不一】中概股盘前涨跌不一，阿里巴巴涨0.45%，拼多多涨0.03%，京东跌0.29%， 百度跌0.39%，理想汽车涨0.95%。 ③【美国官网上线低价版Model Y和Model 3,特斯拉盘前涨1.2%】特斯拉盘前涨超1.2%。消息面上，当 地时间周二，特斯拉官网更新Model Y和Model 3标准版的订购信息。Model Y的标准版目前在美国市场 起售价为3.999万美元，较此前Model Y的起售价便宜约11%。Model 3标准版起售价3.699万美元，为特 斯拉目前最 ...

协议主要条款 对公司影响与风险 本次协议签署将加快奥布替尼及其他管线产品全球开发和商业化进程，是国际化战略重要里程碑，预计 对未来业绩产生积极影响，不影响业务独立性，不会形成依赖。但新药研发风险高、周期长，本次交易 付款需满足条件，最终金额存在不确定性，投资者需谨慎决策。 来源：新浪财经-鹰眼工作室 market诺诚健华10月9日发布公告称，其全资子公司InnoCare Pharma Inc.与Zenas BioPharma, Inc.签署授 权许可协议，将奥布替尼及2项临床前资产有偿许可给Zenas，使其可开发、生产、商业化或以其他方式 利用该等产品。 交易详情 交易审议与双方情况 2025年10月7日，诺诚健华董事会审议通过本次交易，无需提交股东大会审议。主要许可产品：奥布替 尼是处于后期临床阶段、具潜在同类最佳优势的高中枢神经系统渗透性、选择性、不可逆口服小分子 BTK抑制剂。在多发性硬化症领域已启动相关III期临床试验；在自身免疫疾病领域，免疫性血小板减少 症三期注册临床完成患者入组，系统性红斑狼疮IIb期临床数据预计于2025年第四季度公布；在血液肿 瘤领域，自中国上市以来已取得显著临床认可及市场覆 ...

Core Insights - The company announced a licensing agreement with Zenas BioPharma, granting Zenas rights to develop, produce, and commercialize the product Orelabrutinib and two preclinical assets [1][2] Group 1: Licensing Agreement Details - The agreement includes exclusive global rights for Orelabrutinib in multiple sclerosis (MS) and exclusive rights in other non-MS and non-cancer indications outside Greater China and Southeast Asia [1] - The agreement also covers a preclinical IL-17 inhibitor and a preclinical oral TYK2 inhibitor, with exclusive rights outside Greater China and Southeast Asia for the former and global exclusive rights for the latter [1] Group 2: Financial Terms - Zenas will pay the company a $100 million upfront payment and milestone payments, including cash expected upon achieving milestones in 2026, along with 7 million shares of common stock [2] - The total potential payments from this transaction, including upfront, milestone, and commercial payments, could exceed $2 billion [2] - The company is entitled to receive tiered royalties of up to the high teens percentage based on the annual net sales of the licensed products [2]

Core Insights - 诺诚健华 and Zenas BioPharma have entered into a significant licensing agreement, granting Zenas global development and commercialization rights for 奥布替尼 in multiple sclerosis and other non-oncology indications outside Greater China and Southeast Asia [1][2] - The total transaction value exceeds $2 billion, including an upfront payment of up to $100 million, milestone payments, and the issuance of 7 million shares of Zenas common stock [1][2] - 奥布替尼 is a potential best-in-class oral BTK inhibitor with strong CNS penetration, aimed at addressing challenges in the progression of multiple sclerosis [2][3] Company Developments - Zenas will initiate a Phase III clinical trial for 奥布替尼 in primary progressive multiple sclerosis (PPMS) in Q1 2026, following a successful Phase II trial that demonstrated significant efficacy [2][3] - The collaboration is seen as a crucial milestone for 诺诚健华 in its globalization efforts, with expectations of enhancing the clinical and commercial value of 奥布替尼 [3][4] - Zenas aims to advance two additional preclinical molecules, a novel oral IL-17AA/AF inhibitor and a brain-penetrant oral TYK2 inhibitor, into clinical development by 2026 [1][4] Market Potential - 奥布替尼 has shown promising clinical data, significantly reducing the number of new lesions in patients with relapsing-remitting multiple sclerosis (RRMS) [3][4] - The strategic partnership is expected to accelerate the clinical development of 奥布替尼 and maximize its market potential, particularly in the underserved areas of PPMS and secondary progressive multiple sclerosis (SPMS) [3][4] - Zenas is positioned to become a global, integrated biopharmaceutical company focused on the development and commercialization of treatments for autoimmune diseases, leveraging its collaboration with 诺诚健华 [3][4]